Abstract
Methicillin-resistant Staphylococcus aureus (MRSA) is one of the most prevalent multidrug-resistant pathogens worldwide, exhibiting increasing resistance to the latest antibiotic therapies. Here we show that the triple β-lactam combination meropenem-piperacillin-tazobactam (ME/PI/TZ) acts synergistically and is bactericidal against MRSA subspecies N315 and 72 other clinical MRSA isolates in vitro and clears MRSA N315 infection in a mouse model. ME/PI/TZ suppresses evolution of resistance in MRSA via reciprocal collateral sensitivity of its constituents. We demonstrate that these activities also extend to other carbapenem-penicillin–β-lactamase inhibitor combinations. ME/PI/TZ circumvents the tight regulation of the mec and bla operons in MRSA, the basis for inducible resistance to β-lactam antibiotics. Furthermore, ME/PI/TZ subverts the function of penicillin-binding protein-2a (PBP2a) via allostery, which we propose as the mechanism for both synergy and collateral sensitivity. Showing in vivo activity similar to that of linezolid, ME/PI/TZ demonstrates that combinations of older β-lactam antibiotics could be effective against MRSA infections in humans.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Accession codes
Primary accessions
BioProject
Referenced accessions
NCBI Reference Sequence
References
Walsh, T.R., Weeks, J., Livermore, D.M. & Toleman, M.A. Dissemination of NDM-1 positive bacteria in the New Delhi environment and its implications for human health: an environmental point prevalence study. Lancet Infect. Dis. (2011).
Davies, J. & Davies, D. Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74, 417–433 (2010).
Fuda, C.C.S., Fisher, J.F. & Mobashery, S. β-lactam resistance in Staphylococcus aureus: the adaptive resistance of a plastic genome. Cell. Mol. Life Sci. 62, 2617–2633 (2005).
Chambers, H.F. & Deleo, F.R. Waves of resistance: Staphylococcus aureus in the antibiotic era. Nat. Rev. Microbiol. 7, 629–641 (2009).
Malouin, F. & Bryan, L.E. Modification of penicillin-binding proteins of β-lactam resistance. Antimicrob. Agents Chemother. 30, 1–5 (1986).
Fuda, C., Suvorov, M., Vakulenko, S.B. & Mobashery, S. The basis for resistance to β-lactam antibiotics by penicillin-binding protein 2a of methicillin-resistant Staphylococcus aureus. J. Biol. Chem. 279, 40802–40806 (2004).
Fuda, C. et al. Activation for catalysis of penicillin-binding protein 2a from methicillin-resistant Staphylococcus aureus by bacterial cell wall. J. Am. Chem. Soc. 127, 2056–2057 (2005).
Otero, L.H., Rojas-Altuve, A., Llarrull, L.I., Carrasco-López, C. & Kumarasiri, M. How allosteric control of Staphylococcus aureus penicillin binding protein 2a enables methicillin resistance and physiological function. Proc. Natl. Acad. Sci. USA 110, 16808–16813 (2013).
Villegas-Estrada, A., Lee, M., Hesek, D., Vakulenko, S.B. & Mobashery, S. Co-opting the cell wall in fighting methicillin-resistant Staphylococcus aureus: potent inhibition of PBP 2a by two anti-MRSA β-lactam antibiotics. J. Am. Chem. Soc. 130, 9212–9213 (2008).
Long, S.W. et al. PBP2a mutations causing high-level ceftaroline resistance in clinical methicillin-resistant Staphylococcus aureus isolates. Antimicrob. Agents Chemother. 58, 6668–6674 (2014).
Gu, B., Kelesidis, T., Tsiodras, S., Hindler, J. & Humphries, R.M. The emerging problem of linezolid-resistant Staphylococcus. J. Antimicrob. Chemother. 68, 4–11 (2013).
van Hal, S.J., Paterson, D.L. & Gosbell, I.B. Emergence of daptomycin resistance following vancomycin-unresponsive Staphylococcus aureus bacteraemia in a daptomycin-naïve patient-a review of the literature. Eur. J. Clin. Microbiol. Infect. Dis. 30, 603–610 (2011).
Arias, C.A. & Murray, B.E. Antibiotic-resistant bugs in the 21st century—a clinical super-challenge. N. Engl. J. Med. 360, 439–443 (2009).
Bhusal, Y., Shiohira, C.M. & Yamane, N. Determination of in vitro synergy when three antimicrobial agents are combined against Mycobacterium tuberculosis. Int. J. Antimicrob. Agents 26, 292–297 (2005).
Sjölund, M., Wreiber, K., Andersson, D.I., Blaser, M. & Engstrand, L. Long-term persistence of resistant enterococcus species after antibiotics to eradicate Helicobacter pylori. Ann. Intern. Med. 139, 483–487 (2003).
Tupin, A. et al. Resistance to rifampicin: at the crossroads between ecological, genomic and medical concerns. Int. J. Antimicrob. Agents 35, 519–523 (2010).
Comas, I. et al. Whole-genome sequencing of rifampicin-resistant Mycobacterium tuberculosis strains identifies compensatory mutations in RNA polymerase genes. Nat. Genet. 44, 106–110 (2012).
Fischbach, M.A. & Walsh, C.T. Antibiotics for emerging pathogens. Science 325, 1089–1093 (2009).
Zimmermann, G.R., Lehár, J. & Keith, C.T. Multi-target therapeutics: when the whole is greater than the sum of the parts. Drug Discov. Today 12, 34–42 (2007).
Hegreness, M., Shoresh, N., Damian, D., Hartl, D.L. & Kishony, R. Accelerated evolution of resistance in multidrug environments. Proc. Natl. Acad. Sci. USA 105, 13977–13981 (2008).
Lázár, V. et al. Bacterial evolution of antibiotic hypersensitivity. Mol. Syst. Biol. 9, 700 (2013).
Imamovic, L. & Sommer, M.O.A. Use of collateral sensitivity networks to design drug cycling protocols that avoid resistance development. Sci. Transl. Med. 5, 204ra132 (2013).
Boucher, H.W. et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48, 1–12 (2009).
Rice, L.B. Antimicrobial resistance in Gram-positive bacteria. Am. J. Infect. Control 34, S11–S19 (2006).
Waxman, D.J. & Strominger, J.L. Penicillin-binding proteins and the mechanism of action of β-lactam antibiotics. Annu. Rev. Biochem. 52, 825–869 (1983).
Lee, S.H. et al. Antagonism of chemical genetic interaction networks resensitize MRSA to β-lactam antibiotics. Chem. Biol. 18, 1379–1389 (2011).
Koga, T. et al. Affinity of Tomopenem (CS-023) for penicillin-binding proteins in Staphylococcus aureus, Escherichia coli, and Pseudomonas aeruginosa. Antimicrob. Agents Chemother. 53, 1238–1241 (2009).
Yang, Y., Bhachech, N. & Bush, K. Biochemical comparison of imipenem, meropenem and biapenem: permeability, binding to penicillin-binding proteins, and stability to hydrolysis by β-lactamases. J. Antimicrob. Chemother. 35, 75–84 (1995).
Campbell, E.M. & Chao, L. A population model evaluating the consequences of the evolution of double-resistance and tradeoffs on the benefits of two-drug antibiotic treatments. PLoS ONE 9, e86971 (2014).
Munck, C., Gumpert, H.K., Wallin, A.I.N., Wang, H.H. & Sommer, M.O.A. Prediction of resistance development against drug combinations by collateral responses to component drugs. Sci. Transl. Med. 6, 262ra156 (2014).
Kuroda, M. et al. Whole genome sequencing of methicillin-resistant Staphylococcus aureus. Lancet 357, 1225–1240 (2001).
Goldstein, F. et al. Identification and phenotypic characterization of a β-lactam-dependent, methicillin-resistant Staphylococcus aureus strain. Antimicrob. Agents Chemother. 51, 2514–2522 (2007).
Arêde, P., Ministro, J. & Oliveira, D.C. Redefining the role of the β-lactamase locus in methicillin-resistant Staphylococcus aureus: β-lactamase regulators disrupt the MecI-mediated strong repression on mecA and optimize the phenotypic expression of resistance in strains with constitutive mecA. Antimicrob. Agents Chemother. 57, 3037–3045 (2013).
Berenbaum, M.C. What is synergy? Pharmacol. Rev. 41, 93–141 (1989).
Saiman, L. Clinical utility of synergy testing for multidrug-resistant Pseudomonas aeruginosa isolated from patients with cystic fibrosis: 'the motion for'. Paediatr. Respir. Rev. 8, 249–255 (2007).
Clinical and Laboratory Standards Institute. Performance standards for antimicrobial susceptibility testing (document no. M100-S19) (CLSI, Wayne, Pennsylvania, 2009).
Clinical and Laboratory Standards Institute. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: approved standard (CLSI document M07-A8) (CLSI, Wayne, Pennsylvania, 2009).
Fishovitz, J. et al. Disruption of allosteric response as an unprecedented mechanism of resistance to antibiotics. J. Am. Chem. Soc. 136, 9814–9817 (2014).
Somani, P., Freimer, E.H., Gross, M.L. & Higgins, J.T. Pharmacokinetics of imipenem-cilastatin in patients with renal insufficiency undergoing continuous ambulatory peritoneal dialysis. Antimicrob. Agents Chemother. 32, 530–534 (1988).
Kinzig, M., Brismar, B. & Nord, C.E. Pharmacokinetics and tissue penetration of tazobactam and piperacillin in patients undergoing colorectal surgery. Antimicrob. Agents Chemother. 36, 1997–2004 (1992).
Stutman, H.R., Welch, D.F., Scribner, R.K. & Marks, M.I. In vitro antimicrobial activity of aztreonam alone and in combination against bacterial isolates from pediatric patients. Antimicrob. Agents Chemother. 25, 212–215 (1984).
Lee, S.H. et al. Antagonism of chemical genetic interaction networks resensitize MRSA to β-lactam antibiotics. Chem. Biol. 18, 1379–1389 (2011).
Bouley, R. et al. Discovery of antibiotic (E)-3-(3-carboxyphenyl)-2-(4-cyanostyryl)quinazolin-4(3H)-one. J. Am. Chem. Soc. 137, 1738–1741 (2015).
Ankomah, P., Johnson, P.J.T. & Levin, B.R. The pharmaco-, population and evolutionary dynamics of multi-drug therapy: experiments with S. aureus and E. coli and computer simulations. PLoS Pathog. 9, e1003300 (2013).
Sonstein, S.A. & Baldwin, J.N. Loss of the penicillinase plasmid after treatment of Staphylococcus aureus with sodium dodecyl sulfate. J. Bacteriol. 109, 262–265 (1972).
Hackbarth, C.J. & Chambers, H.F. blaI and blaR1 regulate β-lactamase and PBP 2a production in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 37, 1144–1149 (1993).
Lowy, F.D. Antimicrobial resistance: the example of Staphylococcus aureus. J. Clin. Invest. 111, 1265–1273 (2003).
Blázquez, B. et al. Regulation of the expression of the β-lactam antibiotic-resistance determinants in methicillin-resistant Staphylococcus aureus (MRSA). Biochemistry 53, 1548–1550 (2014).
Craig, W.A. The pharmacology of meropenem, a new carbapenem antibiotic. Clin. Infect. Dis. 24 (suppl. 2) S266–S275 (1997).
DeRyke, C.A., Banevicius, M.A., Fan, H.W. & Nicolau, D.P. Bactericidal activities of meropenem and ertapenem against extended-spectrum-β-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a neutropenic mouse thigh model. Antimicrob. Agents Chemother. 51, 1481–1486 (2007).
Cai, Y., Wang, R., Pei, F. & Liang, B.-b. Antibacterial activity of allicin alone and in combination with β-lactams against Staphylococcus spp. and Pseudomonas aeruginosa. J. Antibiot. (Tokyo) 60, 335–338 (2007).
Berenbaum, M.C. A method for testing for synergy with any number of agents. J. Infect. Dis. 137, 122–130 (1978).
NCCLS. Methods for determining bactericidal activity of antimicrobial agents: approved guideline. (NCCLS document no. M26-A) (NCCLS, Wayne, Pennsylvania, 1999).
Li, H. et al. The Sequence Alignment/Map format and SAMtools. Bioinformatics 25, 2078–2079 (2009).
Ford, C.W. et al. In vivo activities of U-100592 and U-100766, novel oxazolidinone antimicrobial agents, against experimental bacterial infections. Antimicrob. Agents Chemother. 40, 1508–1513 (1996).
Acknowledgements
We thank R. Mitra for discussions about SNP calling and NGS data analysis; M. Wallace for MRSA SCCmec typing; B. Wang for technical advice on genomic preparations and sequencing; C. Munck, M. Sommer and J. Lehár regarding prior discussions of 23 antibiotics chosen for combinatorial screening; J. Marasa for screening optimization; J. Fries for optimization of plate reader assays; K. Forsberg for discussions on mechanisms of reciprocal collateral sensitivity; T. Crofts for antibiotic structures in figures; and members of G.D.'s lab for helpful general discussion of the project and manuscript. We thank T. Roemer of Merck Research Laboratories for the kind gift of the antisense strains. This work was supported in part by the NIH Director's New Innovator Award, the National Institute of Diabetes and Digestive and Kidney Diseases and the National Institute of General Medical Sciences of the National Institutes of Health (NIH) under award numbers DP2DK098089 and R01GM099538 to G.D. It is also supported in part by the National Institute of Allergy and Infectious Diseases of the NIH under award numbers AI90818 to M.C. and S.M. and AI104987 to S.M. M.W.P. was supported by the NIGMS Cell and Molecular Biology Training Grant (GM007067). R.B. was supported by T32 GM075762 and by an individual Ruth L. Kirschstein National Research Service Award F31 AI115851 from the NIH. The content is solely the responsibility of the authors and does not necessarily represent the official views of the funding agencies.
Author information
Authors and Affiliations
Contributions
P.R.G. designed the study, performed in vitro experiments, analyzed results and wrote the paper. M.W.P. and C.-A.D.B. analyzed results and wrote the paper. R.B. performed in vivo experiments, analyzed results and wrote the paper. A.B. and B.A.B. performed in vitro experiments and analyzed results. M.A.S., W.R.W. and V.A.S. performed in vivo experiments. S.M. and M.C. designed in vivo experiments, analyzed results and wrote the paper. G.D. designed the study, analyzed results and wrote the paper.
Corresponding author
Ethics declarations
Competing interests
P.R.G., M.W.P., S.M., M.C. and G.D. have submitted provisional US patent application no. 62/190,588 based on the antibiotic combination results described in this study.
Supplementary information
Supplementary Text and Figures
Supplementary Figures 1–3 and Supplementary Tables 1–7. (PDF 3947 kb)
Supplementary Data Set 1
In vivo data for ME/PI/TZ, constituent compounds, and controls in neutropenic mice. (XLSX 59 kb)
Rights and permissions
About this article
Cite this article
Gonzales, P., Pesesky, M., Bouley, R. et al. Synergistic, collaterally sensitive β-lactam combinations suppress resistance in MRSA. Nat Chem Biol 11, 855–861 (2015). https://doi.org/10.1038/nchembio.1911
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/nchembio.1911
This article is cited by
-
Collateral sensitivity to pleuromutilins in vancomycin-resistant Enterococcus faecium
Nature Communications (2022)
-
Rapid expansion and extinction of antibiotic resistance mutations during treatment of acute bacterial respiratory infections
Nature Communications (2022)
-
Repositioning of Disulfiram in Association with Vancomycin Against Enterococcus spp. MDR and XDR
Current Microbiology (2022)
-
Design principles of collateral sensitivity-based dosing strategies
Nature Communications (2021)
-
Synergistic anti-methicillin-resistant Staphylococcus aureus (MRSA) activity and absolute stereochemistry of 7,8-dideoxygriseorhodin C
The Journal of Antibiotics (2020)